Lead Product(s): NBE-002
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 10, 2020
The funds will enable NBE to advance development of the lead asset NBE-002 through early clinical trials and to further strengthen the development team, management and board of the company.